Tumor-derived TGF-β mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer

Journal of Immunotherapy

Volumn 32, Issue 1, 2009, Pages 12-21

  Moo Young, Tricia A ^a,b   Larson, Justin W ^a   Belt, Brian A ^a   Tan, Marcus C ^a   Hawkins, William G ^a   Eberlein, Timothy J ^a   Goedegebuure, Peter S ^a   Linehan, David C ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b Box 8109 ^*  (United States)

Author keywords

Cytokines; Pancreas cancer; Regulatory T cells; Suppression; Tumor growth factor b; Tumor immunity

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNOLOGY; ANIMAL; C57BL MOUSE; ESOPHAGUS TUMOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD4; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PANCREATIC NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 65549158084     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318189f13c     Document Type: Article

References (41)

1. Li G, Ali SA, McArdle SE, et al. Immunity to tumour antigens. Curr Pharm Des. 2005;1 1:3501-3509.
2. Lieberman SM, Horig H, Kaufman HL. Innovative treatments for pancreatic cancer. Surg Clin North Am. 2001;81:715-739.
3. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155:537-547.
4. von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7:925s-932s.
5. Lin Y, Kikuchi S, Tamakoshi A, et al. Serum transforming growth factor-beta 1 levels and pancreatic cancer risk: a nested case-control study (Japan). Cancer Causes Control. 2006; 17: 1077-1082.
6. Yanagimoto H, Takai S, Satoi S, et al. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol. 2005;1 14:52-60.
7. Takahashi K, Toyokawa H, Takai S, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother. 2006;55:775-784.
8. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adeno-carcinoma. J Immunol. 2002;169:2756-2761.
9. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9:4404-4408.
10. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
11. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-949.
12. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
13. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+regulatory T cells. Nat Immunol. 2003;4:330-336.
14. Maggi E, Cosmi L, Liotta F, et al. Thymic regulatory T cells. Autoimmun Rev. 2005;4:579-586.
15. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.Annu Rev Immunol. 2004;22:531-562.
16. Cassis L, Aiello S, Noris M. Natural versus adaptive regulatory T cells. Contrib Nephrol. 2005;146:121-131.
17. Zelenay S, Lopes-Carvalho T, Caramalho I, et al. Foxp3+CD25- CD4T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA. 2005;102: 4091-4096.
18. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cell to CD4+ 25+regulatory T cells by TGF-Beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
19. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6:1219-1227.
20. Fantini MC, Becker C, Tubbe I, et al. TGF-beta induced Foxp3+ regulatory T cells suppress Th1-mediated experimental colitis. Gut. 2005;55:671-680.
21. Linehan DC, Goedegebuure PS. CD25+CD4+ Regulatory T-Cells in Cancer. Immunol Res. 2005;32:155-168.
22. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999;59:3128-3133.
23. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163:5211-5218.
24. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;1 15:3623-3633.
25. Chattopadhyay S, Mehrotra S, Chhabra A, et al. Effect of CD4+CD25+ and CD4+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vito. J Immunol. 2006; 176: 984-990.
26. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol. 2007; 178:2155-2162.
27. Bergmann C, Strauss L, Zeidler R, et al. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother. 2007;56:1429-1442.
28. Powell DJ Jr, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179:4919-4928.
29. Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007;120:2723-2733.
30. Powell DJ Jr, Attia P, Ghetie V, et al. Partial reduction of human FOXP3+ CD4T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother. 2008;31:189-198.
31. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
32. DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005;4: 342-346.
33. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006;29:416-424.
34. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7:1118-1122.
35. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006;177:896-904.
36. Peng Y, Laouar Y, Li MO, et al. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA. 2004;101:4572-4577.
37. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005;23:2078-2093.
38. Barao I, Hanash AM, Hallett W, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA. 2006;103:5460-5465.
39. Lee JC, Lee KM, Kim DW, et al. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172: 7335-7340.
40. Petty CS, Tompkins MB, Tompkins WA. Transforming growth factor-beta/transforming growth factor-betaRII signaling may regulate CD4+CD25+T-regulatory cell homeostasis and suppressor function in feline AIDS lentivirus infection. J Acquir Immune Defic Syndr. 2008;47:148-160.
41. Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25- Tcells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol. 2007;178:2883-2892.